Alembic Pharmaceuticals · NSE: APLLTD · BSE: 533573

Q1 FY20 results · Apr–Jun 2019

Alembic Pharmaceuticals reported revenue from operations of ₹948.91 crore (up 10.0% from Q1 FY19) and net profit of ₹119.49 crore (up 32.1% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY20	Q1 FY19	YoY	Q4 FY19	QoQ
Revenue from operations	948.91	862.53	+10.0%	926.95	+2.4%
Other income	3.29	0.10	33x	3.37	−2.5%
Total income	952.20	862.63	+10.4%	930.32	+2.4%
Profit before share of associates & JVs and tax	155.04	121.92	+27.2%	146.38	+5.9%
Share of profit/(loss) of associates & JVs	0.41	0.07		(7.78)
Net profit for the period	119.49	90.45	+32.1%	123.70	−3.4%
Attributable to shareholders of the company	115.25	90.47	+27.4%	(0.30)	Turned profit
EPS, basic (₹)	6.56	4.80	+36.7%	6.58	−0.3%
Net margin (%)	12.6	10.5		13.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY20	Q1 FY19	YoY	Q4 FY19	QoQ
Revenue from operations	896.74	811.42	+10.5%	848.70	+5.7%
Other income	3.18	0.16	20x	0.89	+257.4%
Total income	899.92	811.58	+10.9%	849.59	+5.9%
Profit before tax	190.80	145.30	+31.3%	122.08	+56.3%
Net profit for the period	155.22	113.98	+36.2%	107.66	+44.2%
EPS, basic (₹)	8.23	6.05	+36.0%	5.71	+44.1%
Net margin (%)	17.3	14.0		12.7

Consolidated

Filed with BSE: 30 Jul 2019, 11:08 IST
Board meeting: 29 Jul 2019
Period: 01 Apr 2019 to 30 Jun 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 30 Jul 2019, 11:08 IST
Board meeting: 29 Jul 2019
Period: 01 Apr 2019 to 30 Jun 2019
Review status: Unaudited
Source: XBRL filing on BSE